Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A5 | Q14940 | 11/20 | 0.54 |
| ▸ | CNR1 | P21554 | 6/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2704394 | 0.88 | CNR1 (0.44) | SLC9A5CNR1EGLN1MAP4K4KMO | |
| SCHEMBL3815469 | 0.87 | MEN1 (0.43) | SLC9A5CNR1EGLN1 | |
| SCHEMBL3818676 | 0.87 | CNR1 (0.44) | SLC9A5CNR1 | |
| SCHEMBL3820627 | 0.86 | SLC9A5 (0.41) | SLC9A5CNR1 | |
| SCHEMBL3812733 | 0.82 | CNR1 (0.48) | SLC9A5CNR1 | |
| SCHEMBL2703218 | 0.78 | CNR1 (0.45) | SLC9A5CNR1MAP4K4KMO | |
| SCHEMBL4013487 | 0.78 | CNR1 (0.50) | SLC9A5CNR1 | |
| SCHEMBL2704945 | 0.75 | CNR1 (0.67) | CNR1MAP4K4KMO | |
| SCHEMBL3812233 | 0.74 | CNR1 (0.46) | CNR1EGLN1MAP4K4KMO | |
| SCHEMBL2703115 | 0.73 | SLC9A5 (0.46) | SLC9A5CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074096-B1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| CN-101460468-B | 2-pyrazinecarboxamide derivatives | HOFFMANN LA ROCHE | 2012-05-30 | — | — | CN | disclosed |
| US-8188093-B2 | Pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2450350-A1 | 3-Pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | F. Hoffmann-La Roche AG (CH) | 2012-05-09 | — | — | EP | disclosed |
| US-20100267745-A1 | 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents | ANDJELKOVIC MIRJANA | 2010-10-21 | — | — | US | disclosed |
| US-7812028-B2 | 3-pyridinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN-LA ROCHE INC. (US) | 2010-10-12 | — | — | US | disclosed |
| US-7629346-B2 | Pyrazinecarboxamide derivatives as CB1 antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-12-08 | — | — | US | disclosed |
| CN-101522626-A | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as HDL-cholesterol raising agents | HOFFMANN LA ROCHE (CH) | 2009-09-02 | — | — | CN | disclosed |
| EP-2035394-B1 | 2-PYRAZINECARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-08-19 | — | — | EP | disclosed |
| EP-2074096-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | ANDJELKOVIC MIRJANA | 2009-06-04 | — | — | US | disclosed |
| EP-1934199-B1 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-04-22 | — | — | EP | disclosed |
| EP-2035394-A1 | 2-PYRAZINECARBOXAMIDE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| CN-101273026-A | Indane derivatives as MCH receptor antagonists | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | CN | disclosed |
| EP-1934199-A2 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | US | disclosed |
| WO-2008040651-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |
| WO-2007147746-A1 | 2-PYRAZINECARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293509-A1 | Pyrazinecarboxamide derivatives as CB1 antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-20 | — | — | US | disclosed |
| WO-2007039462-A2 | INDANE DERIVATIVES AS MCH RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085906-A1 | 3-Pyridinecarboxamide derivatives as HDL-cholesterol raising agents | CETP, APOB, LDLR | SLC9A5 2101/4885CNR1 69/4885EGLN1 1077/4885 |
| US-20070293509-A1 | Pyrazinecarboxamide derivatives as CB1 antagonists | CNR1, CNR2, GPR119 | SLC9A5 889/4885CNR1 1/4885EGLN1 578/4885 |
| US-20090143409-A1 | 3-PYRIDINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | CETP, APOB, LDLR | SLC9A5 2101/4885CNR1 69/4885EGLN1 1077/4885 |
| US-20100267745-A1 | 3-Pyridinecarboxamide Derivatives as HDL-Cholesterol Raising Agents | CETP, APOB, LDLR | SLC9A5 2101/4885CNR1 69/4885EGLN1 1077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.